Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
- Author
- GERGER, Armin1 ; EL-KHOUEIRY, Anthony1 ; BENHAIM, Leonor1 ; PAEZ, David1 ; EL-KHOUEIRY, Rita1 ; ABSENGER, Gudrun4 ; LENZ, Heinz-Josef1 2 3 ; WU ZHANG1 ; DONGYUN YANG2 ; SINGH, Harpreet1 ; BOHANES, Pierre1 ; YAN NING1 ; WINDER, Thomas1 ; LABONTE, Melissa J1 ; WILSON, Peter M1
[1] Division of Medical Oncology, University of Southern California, Los Angeles, California, United States
[2] Department of Preventive Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, United States
[3] USC Center for Molecular Pathways and Drug Discovery, Keck School of Medicine, University of Southern California, Los Angeles, California, United States
[4] Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria - Source
Clinical cancer research (Print). 2011, Vol 17, Num 17, pp 5783-5792, 10 p ; ref : 41 ref
- CODEN
- CCREF4
- ISSN
- 1078-0432
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Angiogenèse Antiangiogénique Anticancéreux Bévacizumab Cancer colorectal Chimiothérapie Facteur croissance endothélium vasculaire Homme Malade Métastase Néovascularisation Oxaliplatine Pharmacogénétique Stade avancé Traitement de première intention Anti-VEGF Agent alkylant Anticorps monoclonal Cancer Génétique Pathologie de l'appareil digestif Pathologie de l'intestin Pathologie du côlon Pathologie du rectum Platine II Complexe Traitement Tumeur maligne
- Keyword (en)
- Angiogenesis Antiangiogenic agent Antineoplastic agent Bevacizumab Colorectal cancer Chemotherapy Vascular endothelium growth factor Human Patient Metastasis Neovascularization Oxaliplatin Pharmacogenetics Advanced stage First line treatment Alkylating agent Monoclonal antibody Cancer Genetics Digestive diseases Intestinal disease Colonic disease Rectal disease Platinum II Complexes Treatment Malignant tumor
- Keyword (es)
- Angiogénesis Antiangiogenico Anticanceroso Bevacizumab Cancer de colon y recto Quimioterapia Factor crecimiento endotelio vascular Hombre Enfermo Metástasis Neovascularización Oxaliplatino Farmacogenética Estadio avanzado Tratamiento de primera línea Agente alquilante Anticuerpo monoclonal Cáncer Genética Aparato digestivo patología Intestino patología Colón patología Recto patología Platino II Complejo Tratamiento Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13B Stomach. Duodenum. Small intestine. Colon. Rectum. Anus / 002B13B01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 24533241
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1158/1078-0432.CCR-11-1115 
https://dx.doi.org/10.1158/1078-0432.CCR-11-1115
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-11-1115\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"5783\";s:8:\"\u0000*\u0000epage\";s:4:\"5792\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GERGER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Armin\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:20:\"EL-KHOUEIRY, Anthony\";i:1;s:15:\"BENHAIM, Leonor\";i:2;s:11:\"PAEZ, David\";i:3;s:17:\"EL-KHOUEIRY, Rita\";i:4;s:16:\"ABSENGER, Gudrun\";i:5;s:17:\"LENZ, Heinz-Josef\";i:6;s:8:\"WU ZHANG\";i:7;s:12:\"DONGYUN YANG\";i:8;s:15:\"SINGH, Harpreet\";i:9;s:15:\"BOHANES, Pierre\";i:10;s:8:\"YAN NING\";i:11;s:14:\"WINDER, Thomas\";i:12;s:18:\"LABONTE, Melissa J\";i:13;s:15:\"WILSON, Peter M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-11-1115\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"5783\";s:8:\"\u0000*\u0000epage\";s:4:\"5792\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GERGER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Armin\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:20:\"EL-KHOUEIRY, Anthony\";i:1;s:15:\"BENHAIM, Leonor\";i:2;s:11:\"PAEZ, David\";i:3;s:17:\"EL-KHOUEIRY, Rita\";i:4;s:16:\"ABSENGER, Gudrun\";i:5;s:17:\"LENZ, Heinz-Josef\";i:6;s:8:\"WU ZHANG\";i:7;s:12:\"DONGYUN YANG\";i:8;s:15:\"SINGH, Harpreet\";i:9;s:15:\"BOHANES, Pierre\";i:10;s:8:\"YAN NING\";i:11;s:14:\"WINDER, Thomas\";i:12;s:18:\"LABONTE, Melissa J\";i:13;s:15:\"WILSON, Peter M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-11-1115\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-11-1115\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"5783\";s:8:\"\u0000*\u0000epage\";s:4:\"5792\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GERGER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Armin\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:20:\"EL-KHOUEIRY, Anthony\";i:1;s:15:\"BENHAIM, Leonor\";i:2;s:11:\"PAEZ, David\";i:3;s:17:\"EL-KHOUEIRY, Rita\";i:4;s:16:\"ABSENGER, Gudrun\";i:5;s:17:\"LENZ, Heinz-Josef\";i:6;s:8:\"WU ZHANG\";i:7;s:12:\"DONGYUN YANG\";i:8;s:15:\"SINGH, Harpreet\";i:9;s:15:\"BOHANES, Pierre\";i:10;s:8:\"YAN NING\";i:11;s:14:\"WINDER, Thomas\";i:12;s:18:\"LABONTE, Melissa J\";i:13;s:15:\"WILSON, Peter M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-11-1115\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"5783\";s:8:\"\u0000*\u0000epage\";s:4:\"5792\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GERGER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Armin\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:20:\"EL-KHOUEIRY, Anthony\";i:1;s:15:\"BENHAIM, Leonor\";i:2;s:11:\"PAEZ, David\";i:3;s:17:\"EL-KHOUEIRY, Rita\";i:4;s:16:\"ABSENGER, Gudrun\";i:5;s:17:\"LENZ, Heinz-Josef\";i:6;s:8:\"WU ZHANG\";i:7;s:12:\"DONGYUN YANG\";i:8;s:15:\"SINGH, Harpreet\";i:9;s:15:\"BOHANES, Pierre\";i:10;s:8:\"YAN NING\";i:11;s:14:\"WINDER, Thomas\";i:12;s:18:\"LABONTE, Melissa J\";i:13;s:15:\"WILSON, Peter M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-11-1115\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:147:\"Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"5783\";s:8:\"\u0000*\u0000epage\";s:4:\"5792\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GERGER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Armin\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:20:\"EL-KHOUEIRY, Anthony\";i:1;s:15:\"BENHAIM, Leonor\";i:2;s:11:\"PAEZ, David\";i:3;s:17:\"EL-KHOUEIRY, Rita\";i:4;s:16:\"ABSENGER, Gudrun\";i:5;s:17:\"LENZ, Heinz-Josef\";i:6;s:8:\"WU ZHANG\";i:7;s:12:\"DONGYUN YANG\";i:8;s:15:\"SINGH, Harpreet\";i:9;s:15:\"BOHANES, Pierre\";i:10;s:8:\"YAN NING\";i:11;s:14:\"WINDER, Thomas\";i:12;s:18:\"LABONTE, Melissa J\";i:13;s:15:\"WILSON, Peter M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:147:\"Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
